Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -3575.07% is 48% below its 1-year average of -2410.81%, around the middle of its 1-year range (-11000.00%–0.00%).
48.29% below its 12-month average of -2410.81%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
-3575.07%
NET PROFIT MARGIN AVG TTM
-2410.81%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
-3.76%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-48.29%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
-95075.24%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 441 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Allarity Therapeutics, Inc.
Market Cap
$15.91M
Net Profit Margin
-3575.07%
TTM Avg
-2410.81%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$16.22M
Net Profit Margin
0.00%
TTM Avg
-6850.00%
3Y Avg
-4251.62%
5Y Avg
-4766.26%
Market Cap
$15.30M
Net Profit Margin
-3011.52%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-79.84%
Market Cap
$16.54M
Net Profit Margin
-219.50%
TTM Avg
-381.91%
3Y Avg
-332.62%
5Y Avg
-409.39%
Market Cap
$16.58M
Net Profit Margin
-106.58%
TTM Avg
-228.29%
3Y Avg
-394.31%
5Y Avg
-410.59%
Market Cap
$14.28M
Net Profit Margin
-651.27%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$13.55M
Net Profit Margin
-8716.77%
TTM Avg
-1649.40%
3Y Avg
-960.30%
5Y Avg
-749.49%
Market Cap
$13.34M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | $15.91M | -3575.07% | -2410.81% | 0.00% | 0.00% |
| BioCardia, Inc. (BCDA)vs › | $16.22M | 0.00% | -6850.00% | -4251.62% | -4766.26% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | -3011.52% | 0.00% | 0.00% | -79.84% |
| Dyadic International, Inc. (DYAI)vs › | $16.54M | -219.50% | -381.91% | -332.62% | -409.39% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.58M | -106.58% | -228.29% | -394.31% | -410.59% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.28M | -651.27% | 0.00% | 0.00% | 0.00% |
| IN8bio, Inc. (INAB)vs › | $13.62M | 0.00% | 0.00% | 0.00% | 0.00% |
| Vyome Holdings, Inc. (HIND)vs › | $13.55M | -8716.77% | -1649.40% | -960.30% | -749.49% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $13.34M | 0.00% | 0.00% | 0.00% | 0.00% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.77M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-3939.1%
Net Profit Margin
-3575.1%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | -11000.00% |
| 2025-12-31 | -1054.06% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | -47.81% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | -3116.51% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | -10616.26% |
| 2019-03-31 | -4356.81% |
| 2018-12-31 | 16887.91% |
| 2018-09-30 | -57.37% |
| 2018-06-30 | 329.08% |
| 2018-03-31 | -219.28% |
| 2017-12-31 | -288.74% |
| 2017-09-30 | -390.70% |
| 2017-06-30 | -177.14% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 1146.35% |
| 2016-09-30 | -693.16% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | -329.16% |
| 2015-12-31 | -197.58% |
| 2015-09-30 | -593.95% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
